3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Withdrawn
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Conditions
Leukemia, Myeloid, Acute
10
Myelodysplastic Syndromes
4
Mycoses
4
Hematologic Neoplasms
3
Neoplasms
2
Leukemia
2
Brain Neoplasms
2
Triple Negative Breast Neoplasms
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Neutropenia
1
Neoplasm, Residual
1
Myelodysplastic-Myeloproliferative Diseases
1
Leukemia, Myeloid
1
Invasive Fungal Infections
1
Glioma
1
Glioblastoma
1
Genetic Predisposition to Disease
1
Candidiasis
1
Bronchiolitis Obliterans Syndrome
1
Breast Neoplasms
1
Bone Marrow Neoplasms
1
Bone Marrow Failure Disorders
1
Aspergillosis
1
Anemia, Aplastic
1
Interventions
Cyclophosphamide
22
blinatumomab
18
Cytarabine
15
fludarabine
13
Azacitidine
12
venetoclax
10
fludarabine phosphate
10
Rituximab
8
Lenalidomide
7
Dexamethasone
7
Methotrexate
6
Daunorubicin
6
Mercaptopurine
5
daratumumab
4
Whole-Body Irradiation
4
Vincristine
4
Melphalan
4
Idarubicin
4
Etoposide
4
Busulfan
4
pembrolizumab
3
obinutuzumab
3
Radiotherapy
3
Maintenance
3
Immunotherapy, Adoptive
3
Imatinib Mesylate
3
Granulocyte Colony-Stimulating Factor
3
Drug Therapy
3
Cladribine
3
Asparaginase
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Neoplasm, Residual
×
posaconazole
×
Clear all
NCT03760445
2020-01-09
HDM201 Added to CT in R/R or Newly Diagnosed AML
Novartis
Phase 1/2
Withdrawn